These data demonstrated a 3.8‐fold reduction of G0S2 expression in CD34+ cells from newly diagnosed CP‐CML patients compared with normal CB, with further downregulation by 3.1‐fold in myeloid BP‐CML (Figure 1A). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.